Use of novel oral anticoagulants increasing in A-fib

Use of novel oral anticoagulants increasing in A-fib

(HealthDay)—For patients with atrial fibrillation hospitalized with stroke or transient ischemic attack, use of novel oral anticoagulants (NOACs) has increased over time, according to a study published online June 9 in Circulation: Cardiovascular Quality and Outcomes.

Priyesh A. Patel, M.D., from the Duke Clinical Research Institute in Durham, N.C., and colleagues identified a cohort of 61,655 atrial fibrillation patients with or , hospitalized between October 2010 and September 2012. The authors characterized the diffusion and patterns of use of warfarin and NOACs (dabigatran or rivaroxaban).

In the patient population, the researchers found that warfarin, dabigatran, and rivaroxaban were prescribed to 88.9, 9.6, and 1.5 percent, respectively. During the study period there was an increase in NOAC use from 0.04 percent to a plateau of 16 to 17 percent. Among eligible patients, anticoagulation rates did not change appreciably (93.7 percent in the first quarter of 2011 to 94.1 percent in the second quarter of 2012), indicative of a trend of switching from warfarin to NOACs. Among those discharged on NOAC versus warfarin therapy, several bleeding risk factors and CHA2DS2-VASc scores were lower.

"NOACs have had modest but growing uptake over time among patients hospitalized with stroke or transient ischemic attack and are prescribed to patients with lower stroke risk compared with ," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2015 HealthDay. All rights reserved.

Citation: Use of novel oral anticoagulants increasing in A-fib (2015, June 15) retrieved 30 January 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Greater decline in renal function with warfarin in A-fib


Feedback to editors